Open AccessDiagnostic efficacy of brafv600e immunocytochemistry in thyroid aspirates in bethesda category iv and papillary thyroid carcinoma
Author(s) -
Nuzhat Husain,
Nidhi Anand,
Tushar Agrawal,
Anurag Gupta,
Saumya Shukla,
Roma Pradhan
Publication year - 2021
Publication title -
journal of cytology/journal of cytology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.267
H-Index - 19
eISSN - 0974-5165
pISSN - 0970-9371
DOI - 10.4103/joc.joc_248_20
Subject(s) - medicine , thyroid carcinoma , immunostaining , pathology , cytology , thyroid , histology , radiology , immunohistochemistry
In papillary thyroid carcinoma (PTC), BRAFV600E is a common mutation and is associated with aggressive clinical behaviour. Immunocytochemistry (ICC) and molecular testing are recommended in the Bethesda System for Reporting Thyroid Cytopathology 2017 (TBSRTC) category III, IV and V.